Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback